Cargando…

Modelling the prevalence of hepatitis B towards eliminating it as a major public health threat in China

BACKGROUND: The World Health Organization (WHO) requires reduction in the prevalence of hepatitis B virus (HBV) surface antigen (HBsAg) in children to 0.1% by 2030, a key indicator for eliminating viral hepatitis as a major public health threat. Whether and how China can achieve this target remains...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Wenjun, Zhuang, Tianyi, Xia, Ruyi, Zou, Zhuoru, Zhang, Lei, Shen, Mingwang, Zhuang, Guihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9195287/
https://www.ncbi.nlm.nih.gov/pubmed/35698098
http://dx.doi.org/10.1186/s12889-022-13594-y
_version_ 1784726933584478208
author Liu, Wenjun
Zhuang, Tianyi
Xia, Ruyi
Zou, Zhuoru
Zhang, Lei
Shen, Mingwang
Zhuang, Guihua
author_facet Liu, Wenjun
Zhuang, Tianyi
Xia, Ruyi
Zou, Zhuoru
Zhang, Lei
Shen, Mingwang
Zhuang, Guihua
author_sort Liu, Wenjun
collection PubMed
description BACKGROUND: The World Health Organization (WHO) requires reduction in the prevalence of hepatitis B virus (HBV) surface antigen (HBsAg) in children to 0.1% by 2030, a key indicator for eliminating viral hepatitis as a major public health threat. Whether and how China can achieve this target remains unknown, although great achievements have been made. We aimed to predict the decline of HBsAg prevalence in China and identify key developments needed to achieve the target. METHODS: An age- and time-dependent dynamic compartmental model was constructed based on the natural history of HBV infection and the national history and current status of hepatitis B control. The model was run from 2006 to 2040 to predict the decline of HBsAg prevalence under three scenarios including maintaining current interventions (status quo), status quo + peripartum antiviral prophylaxis (PAP, recommended by WHO in 2020), and scaling up current interventions + PAP. RESULTS: Under the status quo, HBsAg prevalence would decrease steadily in all age groups, but the WHO’s target of 0.1% prevalence in children aged < 5 years would not be achieved until 2037. The results are robust according to sensitivity analyses. Under the status quo + PAP, the HBsAg prevalence of children aged < 5 years would significantly decrease with the introduction of PAP, and the higher the successful interruption coverage is achieved by PAP, the more significant the decline. However, even if the successful interruption coverage reaches 90% by 2030, the 0.1% prevalence target would not be met until 2031. Under the scaling up current interventions + PAP, combined with scale-up of current interventions, the WHO’s 0.1% target would be achieved on time or one year in advance if PAP is introduced and the successful interruption coverage is scaled up to 80% or 90% by 2030, respectively. CONCLUSIONS: It is difficult for China to achieve the WHO’s target of 0.1% HBsAg prevalence in children by 2030 by maintaining current interventions. PAP may play an important role to shorten the time to achieve the target. A comprehensive scale-up of available interventions including PAP will ensure that China achieves the target on schedule. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12889-022-13594-y.
format Online
Article
Text
id pubmed-9195287
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-91952872022-06-15 Modelling the prevalence of hepatitis B towards eliminating it as a major public health threat in China Liu, Wenjun Zhuang, Tianyi Xia, Ruyi Zou, Zhuoru Zhang, Lei Shen, Mingwang Zhuang, Guihua BMC Public Health Research BACKGROUND: The World Health Organization (WHO) requires reduction in the prevalence of hepatitis B virus (HBV) surface antigen (HBsAg) in children to 0.1% by 2030, a key indicator for eliminating viral hepatitis as a major public health threat. Whether and how China can achieve this target remains unknown, although great achievements have been made. We aimed to predict the decline of HBsAg prevalence in China and identify key developments needed to achieve the target. METHODS: An age- and time-dependent dynamic compartmental model was constructed based on the natural history of HBV infection and the national history and current status of hepatitis B control. The model was run from 2006 to 2040 to predict the decline of HBsAg prevalence under three scenarios including maintaining current interventions (status quo), status quo + peripartum antiviral prophylaxis (PAP, recommended by WHO in 2020), and scaling up current interventions + PAP. RESULTS: Under the status quo, HBsAg prevalence would decrease steadily in all age groups, but the WHO’s target of 0.1% prevalence in children aged < 5 years would not be achieved until 2037. The results are robust according to sensitivity analyses. Under the status quo + PAP, the HBsAg prevalence of children aged < 5 years would significantly decrease with the introduction of PAP, and the higher the successful interruption coverage is achieved by PAP, the more significant the decline. However, even if the successful interruption coverage reaches 90% by 2030, the 0.1% prevalence target would not be met until 2031. Under the scaling up current interventions + PAP, combined with scale-up of current interventions, the WHO’s 0.1% target would be achieved on time or one year in advance if PAP is introduced and the successful interruption coverage is scaled up to 80% or 90% by 2030, respectively. CONCLUSIONS: It is difficult for China to achieve the WHO’s target of 0.1% HBsAg prevalence in children by 2030 by maintaining current interventions. PAP may play an important role to shorten the time to achieve the target. A comprehensive scale-up of available interventions including PAP will ensure that China achieves the target on schedule. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12889-022-13594-y. BioMed Central 2022-06-13 /pmc/articles/PMC9195287/ /pubmed/35698098 http://dx.doi.org/10.1186/s12889-022-13594-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Liu, Wenjun
Zhuang, Tianyi
Xia, Ruyi
Zou, Zhuoru
Zhang, Lei
Shen, Mingwang
Zhuang, Guihua
Modelling the prevalence of hepatitis B towards eliminating it as a major public health threat in China
title Modelling the prevalence of hepatitis B towards eliminating it as a major public health threat in China
title_full Modelling the prevalence of hepatitis B towards eliminating it as a major public health threat in China
title_fullStr Modelling the prevalence of hepatitis B towards eliminating it as a major public health threat in China
title_full_unstemmed Modelling the prevalence of hepatitis B towards eliminating it as a major public health threat in China
title_short Modelling the prevalence of hepatitis B towards eliminating it as a major public health threat in China
title_sort modelling the prevalence of hepatitis b towards eliminating it as a major public health threat in china
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9195287/
https://www.ncbi.nlm.nih.gov/pubmed/35698098
http://dx.doi.org/10.1186/s12889-022-13594-y
work_keys_str_mv AT liuwenjun modellingtheprevalenceofhepatitisbtowardseliminatingitasamajorpublichealththreatinchina
AT zhuangtianyi modellingtheprevalenceofhepatitisbtowardseliminatingitasamajorpublichealththreatinchina
AT xiaruyi modellingtheprevalenceofhepatitisbtowardseliminatingitasamajorpublichealththreatinchina
AT zouzhuoru modellingtheprevalenceofhepatitisbtowardseliminatingitasamajorpublichealththreatinchina
AT zhanglei modellingtheprevalenceofhepatitisbtowardseliminatingitasamajorpublichealththreatinchina
AT shenmingwang modellingtheprevalenceofhepatitisbtowardseliminatingitasamajorpublichealththreatinchina
AT zhuangguihua modellingtheprevalenceofhepatitisbtowardseliminatingitasamajorpublichealththreatinchina